These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32402405)

  • 1. Nitric oxide donating anti-glaucoma drugs: advances and prospects.
    Mao YJ; Wu JB; Yang ZQ; Zhang YH; Huang ZJ
    Chin J Nat Med; 2020 Apr; 18(4):275-283. PubMed ID: 32402405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
    Kaufman PL
    Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide: a drug target for glaucoma revisited.
    Garhöfer G; Schmetterer L
    Drug Discov Today; 2019 Aug; 24(8):1614-1620. PubMed ID: 31173910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide-donating compounds for IOP lowering in glaucoma.
    Andrés-Guerrero V; García-Feijoo J
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Jun; 93(6):290-299. PubMed ID: 29580758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide (NO): an emerging target for the treatment of glaucoma.
    Cavet ME; Vittitow JL; Impagnatiello F; Ongini E; Bastia E
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(8):5005-15. PubMed ID: 25125670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Nitric Oxide for the Treatment of Glaucomatous Disease.
    Aliancy J; Stamer WD; Wirostko B
    Ophthalmol Ther; 2017 Dec; 6(2):221-232. PubMed ID: 28584936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New considerations for the clinical efficacy of old and new topical glaucoma medications.
    MacIver S; Stout N; Ricci O
    Clin Exp Optom; 2021 Apr; 104(3):350-366. PubMed ID: 33725467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
    Hoy SM
    Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
    Fingeret M; Gaddie IB; Bloomenstein M
    Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Application of Nitric Oxide for Ocular Hypertension Treatment.
    Han B; Song M; Li L; Sun X; Lei Y
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting outflow facility in glaucoma management.
    Brubaker RF
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S17-20. PubMed ID: 12852430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of prostaglandins on aqueous humour dynamics and intraocular pressure].
    Raber T
    Klin Monbl Augenheilkd; 2005 Oct; 222(10):802-6. PubMed ID: 16240273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of glaucoma: focus on pharmacological therapy.
    Marquis RE; Whitson JT
    Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabecular meshwork as a new target for the treatment of glaucoma.
    Ferrer E
    Drug News Perspect; 2006 Apr; 19(3):151-8. PubMed ID: 16804567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho kinase inhibitors for glaucoma treatment - Review.
    Germano RA; Finzi S; Challa P; Susanna Junior R
    Arq Bras Oftalmol; 2015; 78(6):388-91. PubMed ID: 26677046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the discovery of novel agents for the treatment of glaucoma.
    Mincione F; Nocentini A; Supuran CT
    Expert Opin Drug Discov; 2021 Oct; 16(10):1209-1225. PubMed ID: 33914670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys.
    Wang RF; Lee PY; Mittag TW; Podos SM; Serle JB; Becker B
    Arch Ophthalmol; 1998 Sep; 116(9):1213-6. PubMed ID: 9747682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nitric oxide in murine conventional outflow physiology.
    Chang JY; Stamer WD; Bertrand J; Read AT; Marando CM; Ethier CR; Overby DR
    Am J Physiol Cell Physiol; 2015 Aug; 309(4):C205-14. PubMed ID: 26040898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of prostaglandin analogues on aqueous humor outflow pathways.
    Winkler NS; Fautsch MP
    J Ocul Pharmacol Ther; 2014; 30(2-3):102-9. PubMed ID: 24359106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.